Quick Takeaways:
- Akston presented data at the 2026 ACVIM Forum showing that its NGF-targeting candidates, AKS-548d and AKS-734, delivered clinically meaningful reductions in canine osteoarthritis pain and improved mobility with a favorable safety profile. In a head-to-head exploratory study, both candidates demonstrated results generally comparable to bedinvetmab (Librela).
- Beyond pain relief, both candidates induced sustained endogenous anti-NGF antibody responses that neutralized the NGF-TrkA pain pathway. AKS-548d also maintained detectable antibody responses for up to four months, supporting the potential for extended dosing intervals, while both therapies were well tolerated with no treatment-related serious adverse events.
- Building on these findings, Akston plans to evaluate AKS-548d and AKS-734 in blinded, placebo-controlled studies involving client-owned dogs with naturally occurring osteoarthritis. The company will also investigate twice-yearly dosing, aiming to reduce the burden of monthly injections while simplifying long-term osteoarthritis management.
Why It Matters?
Akston could emerge as a serious competitor in the fast-growing anti‑NGF OA segment that Zoetis currently leads with its once‑monthly monoclonal. Because Akston’s Ambifect approach stimulates sustained endogenous anti‑NGF antibody responses, AKS‑548d remaining detectable for up to four months, the platform opens the door to twice‑yearly dosing rather than monthly, which would be highly attractive to owners and vets managing chronic OA, and could shift share away from mAb-only regimens if blinded, placebo‑controlled trials in client‑owned dogs confirm comparable efficacy and safety.
Source: PRnewswire
